1. Introduction {#sec1-animals-10-00915}
===============

Insulin-like growth factor 1 (IGF-1) and epidermal growth factor (EGF) are polypeptide mitogens acting through high-affinity tyrosine kinase receptors---IGF-1 receptor (IGF-1R) and EGF receptor (EGFR), respectively \[[@B1-animals-10-00915]\]. The myometrial expression of IGF-1R and EGFR was found in different species. Specifically, the IGF-1R expression was found in humans \[[@B2-animals-10-00915],[@B3-animals-10-00915]\], pigs \[[@B4-animals-10-00915]\] and rats \[[@B5-animals-10-00915]\], whereas the expression of EGFR was demonstrated in human \[[@B2-animals-10-00915]\], mice \[[@B6-animals-10-00915]\] and goat \[[@B7-animals-10-00915]\] myometrium. Past studies have shown that the growth factors may act as regulators of gonadal and embryonic steroidogenesis \[[@B8-animals-10-00915],[@B9-animals-10-00915],[@B10-animals-10-00915],[@B11-animals-10-00915]\]. In mice, EGF was found to reduce ovarian estrogen production \[[@B8-animals-10-00915]\]. The treatment of oocyte-granulosa cells with EGF resulted in increased progesterone (P~4~), testosterone (T) and estradiol-17β (E~2~) release in vitro \[[@B11-animals-10-00915]\]. The in vitro studies performed on human granulosa cells collected from preovulatory follicles showed that EGF stimulates P~4~ and E~2~ release while IGF-1 does not alter ovarian steroidogenic activity \[[@B12-animals-10-00915]\]. In cows, EGF and IGF-1 were found to increase the number of theca cells in vitro, but decreased P~4~ and A~4~ release from the ovarian follicles \[[@B13-animals-10-00915]\]. In pigs, neither IGF-1 nor EGF affected steroid hormone release in vitro from theca cells \[[@B9-animals-10-00915]\] while IGF-1 increased estrogen release in elongating conceptuses \[[@B10-animals-10-00915]\]. It has been established that the porcine myometrium is an important source of steroid hormones \[[@B14-animals-10-00915],[@B15-animals-10-00915],[@B16-animals-10-00915],[@B17-animals-10-00915],[@B18-animals-10-00915]\] and only the effect of several factors, i.e., cytokines, adiponectin and orexins on myometrial steroidogenesis, was determined \[[@B19-animals-10-00915],[@B20-animals-10-00915],[@B21-animals-10-00915],[@B22-animals-10-00915],[@B23-animals-10-00915],[@B24-animals-10-00915]\].

It was hypothesized that IGF-1 and EGF affect myometrial steroidogenesis in cyclic and early pregnant pigs and that porcine myometrium possesses the potential to respond to IGF-1 and EGF treatment via IGF-1 and EGF receptors and the action of IGF-1 and EGF in the myometrium might depend on the physiological status of the female. Therefore, this study aimed to determine: (1) the abundance of EGFR and IGF-1R mRNA transcripts and proteins, and (2) the effect of IGF-1 and EGF on A~4~, T, E~1~ and E~2~ release in vitro in porcine myometrium collected during different days of the estrous cycle and early pregnancy.

2. Materials and Methods {#sec2-animals-10-00915}
========================

All experiments were approved by the Animal Ethics Committee, University of Warmia and Mazury in Olsztyn, Poland (ethical approval number 82/2012/DTN). Postpubertal crossbred pigs (Large White × Polish Landrace), aged 10 months, weighing 90 to 110 kg, were used during the estrous cycle or early pregnancy. Gilts were observed for estrus behavior in the presence of an intact boar. The onset of the second estrus was designated as day 0 of the estrous cycle. Gilts assigned to the early pregnancy group were naturally bred twice---on the 1st and the 2nd day of estrus. The animals on days 10 or 11 (*n* = 5), 12 or 13 (*n* = 5) and 15 or 16 (*n* = 5) of the estrous cycle, and on days 10 or 11 (*n* = 5), 12 or 13 (*n* = 5) and 15 or 16 (*n* = 5) of early pregnancy, were slaughtered in a commercial abattoir and the myometrial slices were collected.

The stage of the estrous cycle was estimated and confirmed based on the morphology of ovaries \[[@B25-animals-10-00915]\]. Pregnancy in mated gilts was confirmed by the presence of embryos after the flushing of each uterine horn with 20 mL of sterile saline. Small sections of the middle part of uterine horns were opened longitudinally on the mesometrial surface and the perimetrium was discarded by careful scraping and slices of the myometrium from the middle part of the uterine horn were then collected with scissors. For gene expression and protein abundance analyses, the myometrial explants were snap-frozen in liquid nitrogen and stored at --80 °C until further analyses. The remaining parts of the uterine horns were placed immediately in ice-cold phosphate-buffered saline (PBS) supplemented with 100 IU/mL penicillin and 100 μg/mL streptomycin and transported to the laboratory on ice for isolation of myometrial slices and in vitro incubation. The timeline of the experiment is presented in [Figure 1](#animals-10-00915-f001){ref-type="fig"}.

2.1. Determination of the Relative Insulin-like Growth Factor 1 Receptor (IGF-1R) and Epidermal Growth Factor Receptor (EGFR) mRNA Transcripts Abundance in the Myometrium {#sec2dot1-animals-10-00915}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The procedure of transcript abundance analysis was performed according to Bustin et al. \[[@B26-animals-10-00915]\]. Total RNA was extracted from 30 mg slices of myometrium *n* = 5 for each examined period) using a peqGOLD TriFastTM (Peqlab, Erlangen, Germany), according to the manufacturer's protocol. The RNA quality and quantity were determined spectrophotometrically (Infinite^®^ 200 PRO, Tecan, Männedorf, Switzerland) and by gel electrophoresis. A 1-µg aliquot of total RNA from each sample was transcribed to cDNA using the QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA, USA) with a mix of oligonucleotide primers and hexamers, according to the manufacturer's protocol. Real-time PCR was performed in triplicate for each sample using a 7300 Real-Time PCR System and SYBR^®^ Green PCR Master Mix (both Life Technologies, Grand Island, NY, USA). The conditions of thermal cycling were: (1) initial denaturation, 10 min, 95 °C (one cycle), (2) denaturation, 15 s, 95 °C, primer annealing, 1 min, 60 °C and elongation, 1 min, 72 °C (40 cycles) followed by a dissociation step (one cycle). Specific primers for *IGF-1R* and *EGFR* mRNAs were designed using Primer-BLAST (National Centre for Biotechnology Information, Bethesda, MD, USA) and controlled using Oligo Calc: Oligonucleotide Properties Calculator software \[[@B27-animals-10-00915]\], Pearl Primer and the mFold web server \[[@B28-animals-10-00915]\]. The primer's efficiency was evaluated by creating a standard curve and it was 96.83% for IGF-1R and 96.58% for EGFR. The reference housekeeping genes and the specific primers for their amplification were selected according to Staszkiewicz et al. \[[@B29-animals-10-00915]\]. The primer sequences are shown in [Table 1](#animals-10-00915-t001){ref-type="table"}. The quantitative gene expression was calculated using the *ΔΔCt* method and normalized using the geometrical means of reference gene expression levels: *β-actin* (*ACTB*) and *18S ribosomal RNA* (*RNA 18S*) \[[@B30-animals-10-00915]\]. Nontemplate controls were used to confirm the amplification specificity for each set of primers.

2.2. Sequence Analysis {#sec2dot2-animals-10-00915}
----------------------

After amplification, the putative *IGF-1R* and *EGFR* amplicons were conducted through gel electrophoresis (2.5% agarose) and isolated using GenElute™ Gel Extraction Kit (NA1111, Lot SLBH5865V, Sigma Aldrich, St. Louis, MO, USA). The obtained amplicons were sequenced by Genomed S.A. (Warsaw, Poland). The specificity of amplified amplicons was confirmed by comparison of their sequences with the sequences of *IGF-1R* and *EGFR* deposited in the National Centre for Biotechnology Information (NCBI) database (NM_214007.1 and NM_214172.1, respectively) and calculation of the statistical significance of the match using the Basic Local Alignment Search Tool (BLAST).

2.3. Determination of the Relative IGF-1R and EGFR Protein Abundance in the Myometrium {#sec2dot3-animals-10-00915}
--------------------------------------------------------------------------------------

The individual myometrial explants were transferred from --80 °C to --20 °C overnight and then cut at --20 °C in a cryostat (Leica, Weltzar, Germany) on 6-µm-thick slices, put on SuperFrost microscope slides and stored at --20 °C. Before immunofluorescence analysis, the slices were thawed in a humid chamber (room temperature) for 30 min and the individual slices were limited with a PapPen marker (Sigma Aldrich, St. Louis, MO, USA) to avoid the outflow of reagents and buffers. The slices were then fixed with 4% paraformaldehyde (P.P.H STANLAB, Lublin, Poland) for 15 min and then washed in PBS (3 × 5 min). Next, the slices were blocked in PBS with 1% Triton X-100 (MP Biomedicals, Solon, OH, USA) and 10% normal donkey serum (LOT: 2572064A, EMD Millipore, Burlington, MA, USA) at 4 °C for 1 h to avoid nonspecific binding of antibodies. After blocking, the slides were washed in PBS (3 × 5 min) and covered with primary antibodies possessing reactivity with pigs, produced in rabbit and diluted in PBS: anti-IGF-1R (1:200, ab90657, Abcam, Cambridge, Great Britain) for IGF-1R detection and localization and anti-EGFR (1:250, ab32430, Abcam, Cambridge, Great Britain) for EGFR detection and localization. The antibodies dilutions were chosen according to the manufacturer's protocols. The slices assigned to the negative control group were covered with PBS. The incubation was performed overnight at 4 °C. The next day, the slices were washed in PBS (3 × 5 min) and covered with donkey anti-rabbit secondary antibodies Alexa Fluor 555 suspended in PBS (1:1500, A31572, LOT 1671993, Life Technologies, Eugene, OR, USA). The labeling of secondary antibodies was performed in darkness to prevent photobleaching, at 4 °C for 1 h. Next, the slices were washed in PBS (3 × 5 min) and mounted with Fluoroshield with DAPI (F6057, LOT: SLBH0683, Sigma Aldrich, St. Louis, MO, USA). Mounted slides were dried at 4 °C and then analyzed using an epifluorescent BX 51 microscope (Olympus, Tokyo, Japan). The images were archived with a digital camera type DP72 (Olympus, Japan), under 400-fold magnification. The data were collected out of 20 fields of each myometrial slice. The intensity of the immunofluorescence signal was calculated with Cell\^F software (Olympus, Tokyo, Japan) and normalized with the intensity of the immunofluorescence signal of negative controls for each group.

2.4. Incubation of Myometrial Slices {#sec2dot4-animals-10-00915}
------------------------------------

Individual myometrial slices (200--210 mg, 3-mm-thick, two slices per each treatment) and dose, i.e., control, IGF-1 (10 or 100 ng/mL) and EGF (10 or 100 ng/mL) from each animal (*n* = 5 per each period of the estrous cycle or pregnancy, i.e., days 10--11, 12--13 and 15--16), were washed twice with PBS supplemented with 100 IU/mL penicillin and 100 μg/mL streptomycin and then placed in culture vials containing 2 mL of Medium 199 (Sigma Aldrich, St. Louis, MO, USA) supplemented with 0.1% bovine serum albumin (BSA) fraction V (Sigma Aldrich, St. Louis, MO, USA) and 20 μg gentamycin (Sigma Aldrich, St. Louis, MO, USA). First, the slices were preincubated in fresh control medium in a shaking water bath at 37 °C in an atmosphere of 95% O~2~ and 5% CO~2~ for 18 h according to the previous studies \[[@B18-animals-10-00915],[@B19-animals-10-00915],[@B23-animals-10-00915]\] and incubated for 6 h in fresh control medium or fresh medium supplemented with IGF-1 (The National Hormone and Peptide Program (NHPP), Dr. A.F. Parlow; 10 ng/mL or 100 ng/mL) or EGF (E4127, Sigma Aldrich, St. Louis, MO, USA 10 ng/mL or 100 ng/mL). The control myometrial slices, i.e., incubated in the control medium without IGF-1 or EGF treatment were prepared for each animal. The duration of in vitro incubation was selected based on the results of the author's previous studies concerning the basal and treatment-stimulated steroidogenesis in the myometrium \[[@B16-animals-10-00915],[@B19-animals-10-00915]\]. The doses of growth factors were selected based on earlier studies: IGF-1 \[[@B31-animals-10-00915]\] and EGF \[[@B32-animals-10-00915]\]. After incubation, the culture vials were placed in an ice bath and the culture medium was collected and frozen at --20 °C until a determination of A~4~, T, E~1~ and E~2~ concentration with radioimmunoassay (RIA).

2.5. Determination of A~4~, T, E~1~ and E~2~ Concentration in the Media {#sec2dot5-animals-10-00915}
-----------------------------------------------------------------------

Concentrations of A~4~, T, E~1,~ and E~2~ in media were determined with RIA, according to the standard protocol used in the previous studies in the author's laboratory and antibodies described by Szafranska et al. \[[@B33-animals-10-00915]\]. The efficiency of extraction for A~4~, T, E~1~ and E~2~ was 85.0% ± 0.1%, 87.1% ± 0.1%, 86.3% ± 0.1% and 84.2% ± 0.1%, respectively. The assay sensitivity for A~4~, T, E~1,~ and E~2~ was 1 pg/mL. The intra- and interassay coefficients of variation for A~4~, T, E~1~ and E~2~ were 0.96%, 1.02%, 0.85%, 1.28%, respectively, and 5.84%, 4.86%, 8.60% and 9.51%, respectively.

2.6. Statistical Analysis {#sec2dot6-animals-10-00915}
-------------------------

All of the data are presented as mean and SEM. Statistical analyses were performed using Statistica v. 13.1 software (Dell, Round Rock, TX, USA). Statistically significant differences were considered with *p* ≤ 0.05. Data obtained with Real-Time PCR were conducted through *ΔΔCt* analysis and 2*^-ΔΔCt^* values were used for statistical calculations. The data obtained with immunofluorescence analysis were normalized to negative controls and used without mathematical transformation. The data obtained with RIA analysis for statistical calculations were log-transformed. The relative abundance of *IGF-1R* and *EGFR* mRNA transcripts and encoded proteins abundance was analyzed with multiway ANOVA followed by Fisher's LSD post hoc test, using a physiological status (the estrous cycle or pregnancy) and day of the estrous cycle or pregnancy (10--11, 12--13 or 15--16) as independent variables. To define the main factors affecting steroid hormones release, a multiway ANOVA, using independent variables was performed, as indicated above. To determine the effect of IGF-1 or EGF treatment within the specific day of the estrous cycle or pregnancy, a one-way ANOVA followed by Dunnett's post hoc test (comparison to the control, i.e., slices of myometrium collected from pigs within the specific day of the estrous cycle or pregnancy and not treated with IGF-1 or EGF) was performed.

3. Results {#sec3-animals-10-00915}
==========

3.1. The Relative Abundance of EGFR and IGF-IR mRNA Transcripts and Proteins in the Myometrium {#sec3dot1-animals-10-00915}
----------------------------------------------------------------------------------------------

### 3.1.1. The Main Effects and Interactions Affecting the Relative Abundance of EGFR and IGF-1R mRNA Transcripts and Proteins {#sec3dot1dot1-animals-10-00915}

The day of the estrous cycle or pregnancy effect was found to have a statistically significant impact on the relative *EGFR* mRNA transcript and protein abundances. The interaction among physiological status and day of the estrous cycle or pregnancy significantly influenced the EGFR protein abundance. The details concerning the *F* statistic value and *p*-value are presented in [Table 2](#animals-10-00915-t002){ref-type="table"}.

### 3.1.2. The Relative IGF-1R and EGFR mRNA Transcript Abundances {#sec3dot1dot2-animals-10-00915}

The relative *IGF-1R* mRNA transcript abundance was significantly lower (*p* ≤ 0.05) during days 12--13 of the estrous cycle compared to days 12--13 of early pregnancy and did not differ (*p* \> 0.05) among the other days of the estrous cycle and pregnancy ([Figure 2](#animals-10-00915-f002){ref-type="fig"}a). The relative *EGFR* mRNA transcript abundance was significantly greater (*p* ≤ 0.05) in myometrial fragments collected during days 15--16 of pregnancy compared to days 12--13 of pregnancy and did not differ (*p* \> 0.05) during the remaining days of the estrous cycle and pregnancy ([Figure 2](#animals-10-00915-f002){ref-type="fig"}b).

### 3.1.3. The IGF-1R and EGFR Protein Location and Abundance {#sec3dot1dot3-animals-10-00915}

IGF-1R and EGFR proteins were found in the circular and longitudinal layers of the myometrium. The representative photographs visualizing the location of IGF-1R and EGFR proteins are presented in [Figure 3](#animals-10-00915-f003){ref-type="fig"} and [Figure 4](#animals-10-00915-f004){ref-type="fig"}. The IGF-1R protein abundance was significantly increased (*p* ≤ 0.05) on days 10--11 and 15--16 of the estrous cycle compared to days 15--16 of pregnancy and was not altered (*p* \> 0.05) compared to the other days of the estrous cycle and early pregnancy ([Figure 5](#animals-10-00915-f005){ref-type="fig"}a). The EGFR protein abundance was the highest (*p* ≤ 0.05) on days 10--11 of pregnancy and 12--13 of the estrous cycle compared to other days of the estrous cycle and early pregnancy ([Figure 5](#animals-10-00915-f005){ref-type="fig"}b).

3.2. The Effect of IGF-1 and EGF on the A~4~, T, E~1~ and E~2~ Release from the Myometrium {#sec3dot2-animals-10-00915}
------------------------------------------------------------------------------------------

### 3.2.1. The Main Effects and Interactions Affecting Myometrial Steroid Hormone Release {#sec3dot2dot1-animals-10-00915}

The main effects and interactions observed among factors affecting steroid hormones release, i.e., treatment, female physiological status and days studied of the estrous cycle or pregnancy, are presented in [Table 3](#animals-10-00915-t003){ref-type="table"}. The A~4~ release was affected by treatment (*p* = 0.037423) and day of the estrous cycle or pregnancy (*p* = 0.000120) and the interaction between physiological status and day of the estrous cycle or pregnancy (*p* = 0.000000). The T release was altered only when physiological status and day of the estrous cycle or pregnancy were interacting (*p* = 0.000000). The E~1~ release was affected by treatment (*p* = 0.009750) and physiological status (*p* = 0.03931). For E~2~ release, none of the main effects were evaluated.

### 3.2.2. Androstenedione (A~4~) and Testosterone (T) Release {#sec3dot2dot2-animals-10-00915}

The A~4~ release from the myometrial slices was significantly increased (*p* ≤ 0.05) only on days 12--13 of the estrous cycle in the presence of EGF (100 ng/mL) when compared to the control ([Figure 6](#animals-10-00915-f006){ref-type="fig"}a). On days 10--11 and 15--16 of the estrous cycle and during all days of pregnancy, neither EGF nor IGF-1 affected the A~4~ release (*p* \> 0.05). IGF-1 and EGF did not alter (*p* \> 0.05) T release from myometrial slices compared to the control in either gravid or nongravid pigs ([Figure 6](#animals-10-00915-f006){ref-type="fig"}b).

### 3.2.3. Estrone (E~1~) and Estradiol-17β (E~2~) Release {#sec3dot2dot3-animals-10-00915}

The myometrial E~1~ release was increased (*p* ≤ 0.05) only on days 15--16 of pregnancy in the presence of IGF-1 (10 and 100 ng/mL) and EGF (100 ng/mL) when compared to the control and did not alter (*p* \> 0.05) in the other days studied of the estrous cycle and pregnancy ([Figure 7](#animals-10-00915-f007){ref-type="fig"}a). The myometrial release of E~2~ was increased (*p* ≤ 0.05) only on days 15--16 of the estrous cycle in the presence of EGF (100 ng/mL, [Figure 7](#animals-10-00915-f007){ref-type="fig"}b).

4. Discussion {#sec4-animals-10-00915}
=============

The current study enriches the knowledge concerning the regulation of myometrial steroidogenesis in pigs. First, this study confirmed that the relative abundance of IGF-1R and EGFR mRNA transcripts and proteins in the myometrium is altered by the female reproductive status. This finding suggests the unequal readiness of porcine myometrium to synthesize IGF-1R and EGFR and respond to IGF-1 and EGF in the following days of the estrous cycle and early pregnancy. Second, this study found that myometrial slices collected during the peri-implantation period and treated in vitro with IGF-1 release relatively greater amounts of E~1~. Moreover, the myometrium treated in vitro with EGF used at the dose of 100 ng/mL release relatively greater amounts of A~4~ when collected during the mid-luteal phase of the estrous cycle, E~2~ when collected during luteolysis, and E~1~ when collected during the peri-implantation period. These notions indicate that in the presence of IGF-1 and EGF, myometrial steroidogenic activity is altered in vitro and the final results differ regarding the physiological status of the female.

Selected days of the estrous cycle and pregnancy (i.e., days 10--11, 12--13 and 15--16) are important for the success of pig reproduction. In gravid gilts, on days 10--11 of pregnancy, embryos enter the uterine horns, start to migrate and enlarge. On days 12--13 of pregnancy, the enlargement of embryos is continued and accelerated and the embryos start their apposition. Finally, on days 15-16 of pregnancy, embryos start the implantation process \[[@B34-animals-10-00915],[@B35-animals-10-00915],[@B36-animals-10-00915],[@B37-animals-10-00915]\]. Days 15--16 of pregnancy are accompanied by the estrogen-controlled prostaglandin F~2~α (PGF~2~α) retrograde transfer from the utero-ovarian vein, which is involved in the protection of corpora lutea (CLs) from luteal regression \[[@B37-animals-10-00915],[@B38-animals-10-00915],[@B39-animals-10-00915]\]. In nonpregnant gilts, days 10--11 and 12--13 of the estrous cycle are recognized as increasing activity of CLs, while days 15--16 the estrous cycle are the period when CLs are regressed and new waves of ovarian follicles are recruited \[[@B37-animals-10-00915],[@B38-animals-10-00915],[@B39-animals-10-00915]\]. Thus, to compare the in vitro effect of IGF-1 and EGF treatment in cyclic and early pregnant pig myometrium, the respective days of the estrous cycle and pregnancy were selected.

The presence of EGF-EGFR in the porcine uterus was previously demonstrated only in the endometrium for rev. \[[@B40-animals-10-00915]\] and uterine arteries \[[@B41-animals-10-00915]\] while a comparative transcriptomic study revealed the abundance of *EGF* mRNA transcript in porcine myometrium \[[@B42-animals-10-00915]\]. Interestingly, during the mid-luteal phase of the estrous cycle, i.e., on days 12--13, the expression of *EGF* mRNA was decreased compared to the respective days of pregnancy \[[@B42-animals-10-00915]\]. The current study demonstrates that myometrial slices collected during the mid-luteal phase of the estrous cycle and exposed in vitro to EGF treatment release greater amounts of A~4~. It is worth noting that during the estrous cycle, the basal myometrial release of A~4~ was greater on days 12--13 than on days 10--11 and 15--16 of the estrous cycle \[[@B18-animals-10-00915]\]. In the current study, it was documented that EGF may be recognized as a potential enhancer of myometrial A~4~ production during the mid-luteal phase of the estrous cycle, but only when used at a higher dose (100 ng/mL). The observed phenomenon can be specific, since the A~4~ release was affected by the treatment, day of the estrous cycle or pregnancy and by the interaction between physiological status and days of the estrous cycle or pregnancy. It was also indicated that specifically during days 12--13 of the estrous cycle, myometrial production of A~4~ in response to EGF treatment is accompanied by an increased abundance of EGFR protein, but not mRNA in the tissue. Interestingly, on days 15--16 of the estrous cycle and early pregnancy, EGF increased the secretion of myometrial estrogens, but the abundance of EGFR protein in the tissue was lowered when compared to tissue during the mid-luteal phase of the estrous cycle, despite the unaltered concentration of *EGFR* mRNA. It is visible that the myometrial expression of EGFR mRNA does not correspond with the abundance of the encoded protein and it is hard to find a strict relation between myometrial EGFR and the effect of EGF on steroid hormone production in this tissue. These alterations may result from transcriptional and post-transcriptional regulations, RNA stability and processing as well as translational and post-translational processes \[[@B43-animals-10-00915],[@B44-animals-10-00915]\]. Low protein concentrations accompanying high gene expression may be caused by the action of RNA interference \[[@B45-animals-10-00915]\]. High protein concentration may suppress mRNA expression and a high level of gene expression may diminish the post-translational modifications and affect the encoded protein level \[[@B46-animals-10-00915]\]. Therefore, the observed no differences in IGF-1R and EGFR mRNAs during the experimental periods accompanying significant differences in IGF-1R protein abundance between days 10--11 and 15--16 of the estrous cycle, and EGFR protein abundance during the estrous cycle and pregnancy is not a surprising phenomenon.

The results from the present study provided evidence that *IGF-1R* mRNA transcript abundance is increased only in pigs during days 12--13 of pregnancy when compared to respective days of the estrous cycle and does not alter when compared to other studied days in pregnant and estrous-cyclic pigs. On the protein level, IGF-1R was increased in cyclic pigs on days 10--11 and 15--16 only when compared to days 15--16 of pregnancy. Thus, myometrial sensitivity to IGF-1 appears to be equal during days 10--11 and 12--13 of the estrous cycle and early pregnancy but is markedly lesser during the peri-implantation period as compared with pigs during luteolysis. Interestingly, in pregnant pigs, the uterine content of IGF-1 is high at the time accompanying rapid elongation of porcine conceptuses and then decreases after day 13th of pregnancy \[[@B47-animals-10-00915]\]. Moreover, IGF-1 was found to function as an enhancer of the aromatase p450 activity in porcine conceptuses \[[@B10-animals-10-00915]\]. It is possible that observed in the current study lesser abundance of myometrial IGF-1R could indirectly prevent oversecretion of E~2~ from the myometrium during the peri-implantation period. It is worth highlighting that the effect of IGF-1 and EGF on E~2~ release during the fetal peri-implantation period was not observed. Interestingly, during the fetal peri-implantation period (days 15--16 of pregnancy) *EGFR* mRNA transcript abundance was markedly greater when compared to the time of maternal recognition of pregnancy (days 12--13 of pregnancy), whereas EGFR protein abundance did not alter. When there is an increased abundance of *EGFR* mRNA, as observed during the periconceptional period, the myometrium should possess greater potential to synthesize EGFR protein, but, possibly due to transcriptional and/or post-transcriptional modifications \[[@B45-animals-10-00915]\] the protein amount is not greater. On the other hand, as the high protein concentration may suppress mRNA expression \[[@B46-animals-10-00915]\], the increased abundance of EGFR protein on days 10--11 of pregnancy could lead to inhibition of *EGFR* mRNA transcript abundance as observed on days 12--13 of pregnancy.

It is worth noting that A~4~ in pigs is the most potent androgen \[[@B48-animals-10-00915]\]. The EGF and A~4~ were found to induce anabolic processes in the target tissue and regulate morphogenesis, cellular proliferation, hyperplasia and aging \[[@B49-animals-10-00915]\]. It is worth noting that the mid-luteal phase of the estrous cycle in pigs is accompanied by increased uterine weight (approximately 40%--60%) compared to the early luteal phase of the estrous cycle \[[@B39-animals-10-00915]\]. This suggests that these morphological changes occurring in the uterus may be mediated by EGF directly, i.e., by the regulation of anabolic processes in the tissue, as well as indirectly, i.e., through the induction of A~4~ synthesis and release from the myometrium. The current study demonstrated that EGF stimulates also myometrial E~2~ production during luteolysis, but only when EGF was used at higher doses. The past in vitro study documented that myometrial E~2~ production can be increased by interleukin 6 (IL6), interleukin 1β (IL1β) and tumor necrosis factor α (TNFα), but only during the peri-implantation period, not during luteolysis \[[@B23-animals-10-00915]\]. Therefore, it appears that EGF, used at higher doses, is the only one acting as an enhancer of myometrial E~2~ production during luteolysis. It is worth noting that myometrial production of E~2~ during luteal regression is about 59% of total uterine E~2~ production and the myometrium appears to be a preferential source of uterine E~2~ \[[@B15-animals-10-00915]\]. Respecting the mechanism of estrogen action \[[@B50-animals-10-00915]\], it cannot be excluded that myometrial E~2~, released in response to EGF, may trigger transcriptional activation of genes expressed in the uterus during luteolysis \[[@B51-animals-10-00915],[@B52-animals-10-00915],[@B53-animals-10-00915]\].

Interestingly, EGF was found to upstream the expression of several genes that were found to be differentially expressed in gilts during the peri-implantation period vs. luteolysis \[[@B53-animals-10-00915]\]. The current study determined, for the first time, that both EGF (100 ng/mL) and IGF-1 (10 and 100 ng/mL) increased myometrial production of E~1~ on days 15--16 of pregnancy. Estrone is known as an estrogen with reduced potency but, via the activity of 17β-hydroxysteroid dehydrogenase (17β-HSD), it may be converted to a more potent E~2~ \[[@B54-animals-10-00915]\]~.~ The presence of 17β-HSD was documented in porcine endometrium \[[@B55-animals-10-00915]\], but it cannot be neglected that the phenomenon of E~1~ to E~2~ conversion may also occur in the myometrium. Thus, EGF (100 ng/mL) and IGF-1 (10 and 100 ng/mL) by stimulating E~1~ release from the myometrium may indirectly cause a greater myometrial production of E~2~ during the peri-implantation period. According to a two-signal switch hypothesis, including the role of E~2~ during early pregnancy in the appearance of prostaglandin F~2~α (PGF~2~α) retrograde transfer and the creation of the increased ratio of PGE~2~ to PGF~2~α \[[@B56-animals-10-00915]\], myometrial E~2~ in gravid pigs may supplement the "rescue switch" from embryo signals to protect CLs.

Interestingly, myometrial production of E~1~ stimulated by IGF-1 during the peri-implantation period occurs despite the decreased concentration of IGF-1R observed in the tissue. This effect may result from the observed decreasing uterine content of IGF binding proteins (IGFBPs), which are responsible for preventing receptor--ligand docking \[[@B57-animals-10-00915]\]. It was found that IGFBPs are synthesized by porcine myometrium \[[@B58-animals-10-00915]\], although the pattern of IGFBPs synthesis and release has not yet been studied.

Previous studies showed that the myometrial production of E~1~ is regulated by a variety of factors. It was demonstrated that orexin A (OXA) and orexin B (OXB) increase the myometrial production of E~1~ in selected studied days of early pregnancy and the estrous cycle in pigs \[[@B20-animals-10-00915],[@B22-animals-10-00915]\]. Other studies showed that the regulation of myometrial E~1~ production may also be physiological-status-related. For example, increased myometrial E~1~ production was observed in response to IL6 during the mid-luteal phase of the estrous cycle (days 12--13) and luteolysis (days 15--16 of the estrous cycle), while in pregnant females the myometrial production of E~1~ was increased in the response of the tissue to IL6 and IL1β action specifically during maternal recognition of pregnancy period, i.e., on days 12--13 of pregnancy \[[@B19-animals-10-00915]\]. In this study, it was demonstrated that in vitro treatment with IGF-1 (10 and 100 ng/mL) and EGF (100 ng/mL) increased myometrial E~1~ production only during the peri-implantation period. Hence, it appears that IGF-1 and EGF, similarly to cytokines, might be recognized as physiological-status-specific enhancers of myometrial E~1~ production.

5. Conclusions {#sec5-animals-10-00915}
==============

In conclusion: (1) in porcine myometrium, EGF, used at a dose of 100 ng/mL, significantly increases A~4~ during the mid-luteal phase of the estrous cycle and E~2~ release during luteolysis; (2) during the peri-implantation period, IGF-1 and EGF increase myometrial E~1~ secretion; (3) EGF, by increasing myometrial A~4~ production, may provide a substrate for estrogen synthesis and affect myometrial morphogenesis during the mid-luteal phase of the estrous cycle; (4) both IGF-1 and EGF contribute to increasing the intrauterine content of estrogens of a myometrial source during luteolysis and the peri-implantation period.

The authors would like to thank Genowefa Kotwica for her scientific support and consultations, Bartosz Wojciechowicz for technical assistance with in vitro incubation, Kamila Zglejc-Waszak and Marcin Martyniak, for assistance during the collection of tissues, and Janina Bukowska for performing the RIA analysis. We also thank our students: Natalia Pietrzak, Dominika Pyt, and Rafal Falisz, for excellent technical assistance during the immunofluorescence analyses and making these long hours in darkness a little bit shorter and brighter.

Conceptualization, E.M.W., and A.F.; methodology, E.M.W., and A.F.; software, E.M.W.; validation, A.Z.; formal analysis, E.M.W., and A.F.; investigation, E.M.W., W.K., A.Z., and A.F.; resources, E.M.W. and A.Z.; data curation, E.M.W.; writing---original draft preparation, E.M.W., and A.F.; writing---review and editing, E.M.W., W.K., A.Z., and A.F.; visualization, E.M.W., W.K.; supervision, A.F.; project administration, E.M.W., and A.F.; funding acquisition, E.M.W., and A.F. All authors have read and agreed to the published version of the manuscript.

This research was funded by the University of Warmia and Mazury in Olsztyn, Poland, grant number 12.610.005-300 and 12.620.033-300" and partially by National Science Centre, Poland, grant number 2017/25/B/NZ9/00090 (recipient A.F).

The authors declare no conflicts of interest. The funders had no role in the design of the study, in the collection, analyses and interpretation of data, the writing of the manuscript or in the decision to publish the results.

![The timeline of the experiment.](animals-10-00915-g001){#animals-10-00915-f001}

![The relative abundance of (**a**) *IGF-1R* and (**b**) EGFR mRNA transcripts in the myometrium collected from pigs during the estrous cycle (days 10--11, 12--13 and 15--16) and corresponding days of early pregnancy (multiway ANOVA, Fisher's LSD post hoc test). Statistically significant differences were considered at *p* ≤ 0.05 and indicated as lower-case letters (a,b) above the bars.](animals-10-00915-g002){#animals-10-00915-f002}

![The representative photographs showing (**a**) IGF-1R immunostaining, (**b**) negative control, and (**c**) the myometrial location of IGF-1R during days 10--11, 12--13 and 15--16 of the estrous cycle and days 10--11, 12--13 and 15--16 of pregnancy. Magnification 400×. CM---circular muscle; LM---longitudinal muscle. The nuclei are stained with DAPI (**blue**) and IGF-1R sites are stained with Alexa Fluor 555 (**red**).](animals-10-00915-g003){#animals-10-00915-f003}

![The representative photographs showing (**a**) EGFR immunostaining, (**b**) negative control, and (**c**) the myometrial location of EGFR during days 10--11, 12--13 and 15--16 of the estrous cycle and days 10--11, 12--13 and 15--16 of pregnancy. Magnification 400×. CM---circular muscle; LM---longitudinal muscle. The nuclei are stained with DAPI (**blue**) and EGFR sites are stained with Alexa Fluor 555 (**red**).](animals-10-00915-g004){#animals-10-00915-f004}

![The relative abundance of (**a**) IGF-1R and (**b**) EGFR proteins in the myometrium collected from pigs during the estrous cycle (days 10--11, 12--13 and 15--16) and corresponding days of early pregnancy (multiway ANOVA, Fisher's LSD post hoc test). Statistically significant differences were considered at *p* ≤ 0.05 and indicated as lower-case letters (a,b) above the bars.](animals-10-00915-g005){#animals-10-00915-f005}

![The concentration of (**a**) androstenedione and (**b**) testosterone in media collected after in vitro incubation of myometrial slices treated with IGF-1 (10 and 100 ng/mL) or EGF (10 and 100 ng/mL, one-way ANOVA, Dunnett's post hoc test). Statistically significant differences were considered at *p* ≤ 0.05 and indicated as lower-case letters (a,b) above the bars.](animals-10-00915-g006){#animals-10-00915-f006}

![The concentration of (**a**) estrone and (**b**) estradiol-17β in media collected after in vitro incubation of myometrial slices treated with IGF-1 (10 and 100 ng/mL) or EGF (10 and 100 ng/mL, one-way ANOVA, Dunnett's post hoc test). Statistically significant differences were considered at *p* ≤ 0.05 and indicated as lower-case letters (a,b) above the bars.](animals-10-00915-g007){#animals-10-00915-f007}
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###### 

Used primer sequences.

  --------------------------------------------------------------------------------------------------------
  Gene Symbol   Primer Sequence (5'→3')      Gene Bank Accession No.   Annealing\   Amplicon Length (bp)
                                                                       (°C)         
  ------------- ---------------------------- ------------------------- ------------ ----------------------
  *IGF-1R*      F: TTTGTGCCCAGACCTGAACG\     NM_214172.1               60           200
                R: GTAAAAGGCCGGAGGTTGGA                                             

  *EGFR*        F: TTCCGTCCGAAACAATCGG\      NM_214007.1               60           103
                R: TTCCCAGTGAGGCACAGAG                                              

  *ACTB*        F: GGAGATCGTGCGGGACATCAAG\   U07786.1                  60           268
                R: GGCGTAGAGGTCCTTCCTGATG                                           

  *RNA 18S*     F: ACTGAGGCCATGATTAAG\       AF102857.1                60           521
                R: GCTATCAATCTGTCAATCC                                              
  --------------------------------------------------------------------------------------------------------
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###### 

*Insulin-like Growth Factor 1 Receptor* (*IGF-IR*) and *Epidermal Growth Factor Receptor* (*EGFR*) mRNAs expression and EGFR and IGF-IR protein abundance---the main effects and the interactions observed among factors (multiway ANOVA).

  Effect                                                         *IGF-1R* mRNA          *EGFR* mRNA                          
  -------------------------------------------------------------- ---------------------- -------------------- --------------- ----------
  Physiological status ^1^                                       2.44879                0.136039             0.09807         0.757970
  Day of the estrous cycle or pregnancy ^2^                      0.45379                0.642693             3.71779         0.045775
  Physiological status × Day of the estrous cycle or pregnancy   0.38678                0.685068             0.13592         0.873849
  **Effect**                                                     ***IGF-1R* Protein**   ***EGFR* Protein**                   
  ***F***                                                        ***p*-Value**          ***F***              ***p*-Value**   
  Physiological status ^1^                                       3.8520                 0.065331             0.0022          0.962905
  Day of the estrous cycle or pregnancy ^2^                      1.9167                 0.175939             4.2889          0.029976
  Physiological status × Day of the estrous cycle or pregnancy   1.1946                 0.325719             12.9711         0.000325

^1^ The estrous cycle or pregnancy; ^2^ Days 10--11, 12--13 or 15--16.
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###### 

Myometrial A~4~, T, E~1~ and E~2~ release---the main effects and the interactions observed among factors (multiway ANOVA).

  Factors                                                                     A~4~     T          E~1~    E~2~                                  
  --------------------------------------------------------------------------- -------- ---------- ------- ---------- ------- ---------- ------- ----------
  Treatment ^1^                                                               2.659    0.037423   0.36    0.836151   3.529   0.009750   1.111   0.355716
  Physiological status ^2^                                                    1.378    0.243377   5.85    0.017356   8.716   0.003931   1.627   0.205110
  Days of the estrous cycle or pregnancy ^3^                                  9.939    0.000120   2.39    0.096971   1.312   0.273793   2.081   0.130233
  Treatment × Physiological status                                            0.169    0.953780   0.21    0.931675   0.481   0.749270   1.470   0.216833
  Treatment × Days of the estrous cycle or pregnancy                          0.743    0.653462   0.90    0.517208   0.723   0.670727   1.212   0.299688
  Physiological status × Days of the estrous cycle or pregnancy               17.850   0.000000   18.44   0.000000   2.838   0.063284   2.402   0.095745
  Treatment × Physiological status × Days of the estrous cycle or pregnancy   0.167    0.994718   0.44    0.895146   0.845   0.565218   0.381   0.928360

^1^ IGF-1 or EGF (10 ng/mL or 100 ng/mL); ^2^ The estrous cycle or pregnancy; ^3^ Days 10--11, 12--13 or 15--16.
